Drug Trial Radar · NCT02134028
Long-Term Safety Evaluation of Dupilumab in Patients With Asthma (LIBERTY ASTHMA TRAVERSE)
Last checked: Nov 20, 2026Latest source record: Mar 28, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,282
Actual
Start
Aug 5, 2014
Primary completion
Oct 11, 2019
Study completion Oct 11, 2019
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- Collaborators
- Regeneron Pharmaceuticals
- First posted
- May 8, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary Objective: To evaluate the long-term safety and tolerability of dupilumab in participants with asthma who participated in a previous dupilumab asthma study (DRI12544, PDY14192, EFC13579, EFC13691). Secondary Objectives: To evaluate the long-term efficacy of dupilumab in participants with asthma who participated in a previous dupilumab asthma clinical study. To evaluate dupilumab in participants with asthma who participated in a previous dupilumab asthma clinical study, with regards to: * Systemic exposure * Anti-drug antibodies * Biomarkers
Conditions
- Asthma
Interventions
DupilumabDrug
Pharmaceutical form: Solution for injection Routes of administration: Subcutaneous
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-Emergent Adverse Events (TEAEs)Time frame: From the first IMP injection in LTS12551 to the last IMP injection plus 14 weeks (up to 108 weeks)
Locations
365 sites in 27 countries. Site status is shown where the registry gives one.
Investigational Site Number 840047
Birmingham, Alabama
Investigational Site Number 840099
Gilbert, Arizona
Investigational Site Number 840087
Scottsdale, Arizona
Investigational Site Number 840402
Tucson, Arizona
Investigational Site Number 840132
Little Rock, Arkansas
Investigational Site Number 840109
Bakersfield, California
Investigational Site Number 840045
Long Beach, California
Investigational Site Number 840019
Los Angeles, California
Investigational Site Number 840029
Los Angeles, California
Investigational Site Number 840022
Los Angeles, California
Investigational Site Number 840044
Newport Beach, California
Investigational Site Number 840041
North Hollywood, California
Investigational Site Number 840014
Rolling Hills Estates, California
Investigational Site Number 840121
San Jose, California
Investigational Site Number 840040
Colorado Springs, Colorado
Investigational Site Number 840403
Denver, Colorado
Investigational Site Number 840006
Denver, Colorado
Investigational Site Number 840024
Denver, Colorado
Investigational Site Number 840130
Denver, Colorado
Investigational Site Number 840902
New Haven, Connecticut
Investigational Site Number 840137
Aventura, Florida
Investigational Site Number 840071
Gainesville, Florida
Investigational Site Number 840115
Ocoee, Florida
Investigational Site Number 840055
Sarasota, Florida
Investigational Site Number 840079
Twin Falls, Idaho
Investigational Site Number 840101
Chicago, Illinois
Investigational Site Number 840032
Fort Mitchell, Kentucky
Investigational Site Number 840017
Louisville, Kentucky
Investigational Site Number 840030
Owensboro, Kentucky
Investigational Site Number 840064
Bangor, Maine
Investigational Site Number 840052
Chevy Chase, Maryland
Investigational Site Number 840073
Gaithersburg, Maryland
Investigational Site Number 840080
Owings Mills, Maryland
Investigational Site Number 840401
Boston, Massachusetts
Investigational Site Number 840018
Minneapolis, Minnesota
Investigational Site Number 840002
St Louis, Missouri
Investigational Site Number 840102
St Louis, Missouri
Investigational Site Number 840093
St Louis, Missouri
Investigational Site Number 840037
Missoula, Montana
Investigational Site Number 840078
Omaha, Nebraska
Showing 40 of 365 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.